BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28279985)

  • 1. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
    Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
    AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
    Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
    Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
    AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
    Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
    J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
    Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
    Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.
    Elson A; Bovi J; Siker M; Schultz C; Paulson E
    J Neurooncol; 2015 May; 122(3):549-58. PubMed ID: 25700835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
    Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
    J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.
    Ellingson BM; Cloughesy TF; Zaw T; Lai A; Nghiemphu PL; Harris R; Lalezari S; Wagle N; Naeini KM; Carrillo J; Liau LM; Pope WB
    Neuro Oncol; 2012 Mar; 14(3):333-43. PubMed ID: 22270220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of Restriction Spectrum Imaging in the characterization of the peritumoral brain zone in glioblastoma: Analysis of overall and progression-free survival.
    Latysheva A; Geier OM; Hope TR; Brunetti M; Micci F; Vik-Mo EO; Emblem KE; Server A
    Eur J Radiol; 2020 Nov; 132():109289. PubMed ID: 33002815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival.
    Choi YS; Kim DW; Lee SK; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Ahn SS
    AJNR Am J Neuroradiol; 2015 Dec; 36(12):2235-41. PubMed ID: 26338911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastomas with and without peritumoral fluid-attenuated inversion recovery (FLAIR) hyperintensity present morphological and microstructural differences on conventional MR images.
    Han Q; Lu Y; Wang D; Li X; Ruan Z; Mei N; Ji X; Geng D; Yin B
    Eur Radiol; 2023 Dec; 33(12):9139-9151. PubMed ID: 37495706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.
    John F; Bosnyák E; Robinette NL; Amit-Yousif AJ; Barger GR; Shah KD; Michelhaugh SK; Klinger NV; Mittal S; Juhász C
    Neuro Oncol; 2019 Feb; 21(2):264-273. PubMed ID: 30346623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
    Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions.
    Kim SH; Cho KH; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST
    AJNR Am J Neuroradiol; 2019 Dec; 40(12):2052-2058. PubMed ID: 31727756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
    Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
    AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma.
    Wahl DR; Kim MM; Aryal MP; Hartman H; Lawrence TS; Schipper MJ; Parmar HA; Cao Y
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):757-764. PubMed ID: 29980414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.